纳米医学
药物输送
风险分析(工程)
IVIVC公司
计算机科学
细胞外小泡
靶向给药
纳米技术
生化工程
医学
药理学
药品
工程类
生物
细胞生物学
纳米颗粒
材料科学
生物制药分类系统
溶解试验
作者
Marc-Phillip Mast,Harshvardhan Modh,Carole Champanhac,Jiong‐Wei Wang,G. Storm,Johannes Krämer,Volker Mailänder,Giorgia Pastorin,Matthias G. Wacker
标识
DOI:10.1016/j.addr.2021.113829
摘要
For many years, nanomedicine is pushing the boundaries of drug delivery. When applying these novel therapeutics, safety considerations are not only a key concern when entering clinical trials but also an important decision point in product development. Standing at the crossroads, nanomedicine may be able to escape the niche markets and achieve wider acceptance by the pharmaceutical industry. While there is a new generation of drug delivery systems, the extracellular vesicles, standing on the starting line, unresolved issues and new challenges emerge from their translation from bench to bedside. Some key features of injectable nanomedicines contribute to the predictability of the pharmacological and toxicological effects. So far, only a few of the physicochemical attributes of nanomedicines can be justified by a direct mathematical relationship between the in vitro and the in vivo responses. To further develop extracellular vesicles as drug carriers, we have to learn from more than 40 years of clinical experience in liposomal delivery and pass on this knowledge to the next generation. Our quick guide discusses relationships between physicochemical characteristics and the in vivo response, commonly referred to as in vitro-in vivo correlation. Further, we highlight the key role of computational methods, lay open current knowledge gaps, and question the established design strategies. Has the recent progress improved the predictability of targeted delivery or do we need another change in perspective?
科研通智能强力驱动
Strongly Powered by AbleSci AI